For example, CA-170, is an oral inhibitor which targets both PD-L1 and VISTA revealed remarkable anti-tumor effects in preclinical study and the phase I trial in patients with advanced solid tumors including melanoma is currently investigated (NCT02812875)22. Here, CD274 is linked to neoplasm.